Amendments to the Claims Pursuant to
37 C.F.R. § 1.121 Revised Format

We claim:

1. (currently amended) A compound of the formula:



wherein

B is $CONR^a$, NR^aCO, NR^aCO_2 or NR^aCONR^a;

R^a represents hydrogen or (1-6C) alkyl,

q is ~~zero or~~ 1;

R^1 represents a ~~naphthyl group or a~~ phenyl, ~~furyl, thienyl or pyridyl group which is unsubstituted or~~ substituted by ~~one or two substituents selected independently from halogen; nitro; cyano; hydroxyimino; (1-10C)alkyl; (2-10C)alkenyl; (2-10C)alkynyl; (3-8C)cycloalkyl; hydroxy(3-8C)cycloalkyl; oxo(3-8C)cycloalkyl; halo(1-10C)alkyl; $(CH_2)_yX^1R^9$ in which y is 0 or an integer of from 1 to 4, X^1 represents O, S, NR^{10}, CO, COO, OCO, $CONR^{11}$, $NR^{12}CO$, $NR^{12}COCOO$ or $OCONR^{13}$, R^9 represents hydrogen, (1-10C)alkyl, (3-10C)alkenyl, (3-10C)alkynyl, pyrrolidinyl, tetrahydrofuryl, morpholino or (3-8C)cycloalkyl and R^{10}, R^{11}, R^{12} and R^{13} each independently represents hydrogen or (1-10C)alkyl, or R^9 and R^{10}, R^{11}, R^{12} or R^{13} together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group; N-(1-4C)alkylpiperazinyl; N-phenyl(1-4C)alkylpiperazinyl;~~ thienyl; ~~furyl; oxazolyl; isoxazolyl; pyrazolyl; imidazolyl; thiazolyl; pyridyl; pyridazinyl; pyrimidinyl; dihydro-thienyl; dihydrofuryl; dihydrothiopyranyl; dihydropyranyl; dihydrothiazolyl; (1-4C)alkoxycarbonyldihydrothiazolyl; (1-4C)alkoxycarbonyldimethyldihydrothiazolyl; tetrahydro-thienyl; tetrahydrofuryl; tetrahydrothiopyranyl; tetrahydropyranyl; indolyl; benzofuryl; benzothienyl; benzimidazolyl; and a group of formula R^{14}-$(L^a)_n$-X^2-$(L^b)_m$ in~~

~~which X^2 represents a bond, O, NH, S, SO, SO_2, CO, CH(OH), CONH, NHCO, NHCONH, NHCOO, COCONH, OCH_2CONH or CH=CH, L^a and L^b each represent (1-4C)alkylene, one of n and m is 0 or 1 and the other is 0, and R^{14} represents a phenyl or heteroaromatic group which is unsubstituted or substituted by one or two of halogen, nitro, cyano, hydroxyimino, (1-10C) alkyl, (2-10C)alkenyl, (2-10C)alkynyl, (3-8C) cycloalkyl, 4-(1,1-dioxotetrahydro-1,2-thiazinyl), halo(1-10C)alkyl, cyano(2-10C)alkenyl, phenyl, and $(CH_2)_zX^3R^{15}$ in which z is 0 or an integer of from 1 to 4, X^3 represents O, S, NR^{16}, CO, CH(OH), COO, OCO, $CONR^{17}$, $NR^{18}CO$, $NHSO_2$, $NHSO_2NR^{17}$, NHCONH, $OCONR^{19}$ or $NR^{19}COO$, R^{15} represents hydrogen, (1-10C)alkyl, phenyl(1-4C)alkyl, halo(1-10C)alkyl, (1-4C)alkoxycarbonyl(1-4C)alkyl, (1-4C)alkylsulfonylamino(1-4C)alkyl, (N-(1-4C)alkoxycarbonyl)(1-4C)alkylsulfonylamino-(1-4C)alkyl, (3-10C)alkenyl, (3-10C)alkynyl, (3-8C) cycloalkyl, camphoryl or an aromatic or heteroaromatic group which is unsubstituted or substituted by one or two of halogen, (1-4C)alkyl, halo(1-4C)alkyl, di(1-4C)alkylamino and (1-4C)alkoxy and R^{16}, R^{17}, R^{18} and R^{19} each independently represents hydrogen or (1-10C)alkyl, or R^{15} and R^{16}, R^{17}, R^{18} or R^{19} together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl or morpholino group;~~

R^2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO_2(1-4C)alkyl, phenyl(1-6C)alkyl, ~~heteroaromatic~~, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, ~~or a group of formula R^3R^4N in which R^3 and R^4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group;~~ and

R^5, R^6, and R^7 represent hydrogen;

R^8 represents methyl;

~~R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of hydrogen, (1-6C)alkyl; aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or~~

~~two of R^5, R^6, R^7 and R^8 together with the carbon atom or carbon atoms to which they are attached form a (3-8C) carbocyclic ring; and the remainder of R^5, R^6, R^7 and R^8 represent hydrogen;~~ or a pharmaceutically acceptable salt thereof~~;~~

~~with the proviso that when R^2 represents R^3R^4N, then B is other than NR^aCONR^a or $CONR^a$.~~

2. (original) A compound according to claim 1 wherein B is $CONR^a$.

3. (original) A compound according to claim 1 wherein B is NR^aCO.

4. (original) A compound according to claim 1 wherein B is NR^aCO_2.

5. (original) A compound according to claim 1 wherein B is NR^aCONR^a.

6. (cancelled)

7. (currently amended) A compound as claimed in claim 1 ~~any one of claims 1 to 5~~ wherein R^a is hydrogen.

8. (currently amended) A compound as claimed in claim 1 ~~any one of claims 1 to 5~~ wherein R^2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl 1-4C)alkoxy(1-4C)alkyl, ~~heteroaromatic~~, or phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy.

9. (currently amended) A compound according to claim 8 wherein R^2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl ~~or heteroaromatic~~, or phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy.

10. (currently amended) A compound according to claim 9 wherein R^2 represents methyl, ethyl, isopropyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, isovaleryl, phenyl, or benzyl. ~~, 2-furyl, 2-thienyl, 5-oxazoyl, 2-pyridyl, 3-pyridyl, 4-pryidyl~~

11. (cancelled)

12. (cancelled)

13. (cancelled)

14. (currently amended) A compound as claimed in Claim 1, which is selected from:

a	
b	
c	
d	
e	
f	
g	

h	
i	
j	
k	
m	
n	
o	
p	
q	
r	

s	
t	
u	
v	
w	
x	
y	
z	
aa	
bb	

cc	
dd	
ee	
ff	
gg	
hh	
ii	
jj	
kk	
mm	

nn	
oo	
pp	
qq	
rr	
tt	
uu	
vv	
xx	
yy	

zz	 ,
aaa	 , and
bbb	 ; and

pharmaceutically acceptable salts thereof.

15. (original) A pharmaceutical composition, which comprises a compound as claimed in claim 1 and a pharmaceutically acceptable diluent or carrier.

16. (currently amended) A method of potentiating glutamate receptor function in a mammal requiring such treatment, which comprises administering an effective amount of a compound of formula:



wherein

B is $CONR^a$, NR^aCO, NR^aCO_2 or NR^aCONR^a;

R^a represents hydrogen or (1-6C) alkyl,

q is ~~zero or~~ 1;

R^1 represents ~~an unsubstituted or substituted aromatic or heteroaromatic group~~ a phenyl substituted by thienyl;

R^2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO_2(1-4C)alkyl, phenyl(1-6C)alkyl, heteroaromatic, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, ~~or a group of formula R^3R^4N in which R^3 and R^4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl,~~

~~pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group;~~ and

R^5, R^6, and R^7 represent hydrogen;

R^8 represents methyl;

~~R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of hydrogen, (1-6C)alkyl; aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or~~

~~two of R^5, R^6, R^7 and R^8 together with the carbon atom or carbon atoms to which they are attached form a (3-8C) carbocyclic ring; and the remainder of R^5, R^6, R^7 and R^8 represent hydrogen;~~ or a pharmaceutically acceptable salt thereof.

~~with the proviso that when R^2 represents R^3R^4N, then B is other than NR^aCONR^a or $CONR^a$.~~

17. (cancelled)

18. (currently amended) A method of treating a cognitive disorder; a neurodegenerative disorder; age-related dementia; age-induced memory impairment; movement disorder; reversal of a drug-induced state; depression; attention deficit disorder; attention deficit hyperactivity disorder; psychosis; cognitive deficits associated with psychosis; or drug-induced psychosis in a patient, which comprises administering to a patient in need thereof an effective amount of a compound of formula:



wherein

B is $CONR^a$, NR^aCO, NR^aCO_2 or NR^aCONR^a;

R^a represents hydrogen or (1-6C) alkyl,

q is ~~zero or~~ 1;

R^1 represents ~~an unsubstituted or substituted aromatic or heteroaromatic group~~ a phenyl substituted by thienyl;

R^2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO_2(1-4C)alkyl, phenyl(1-6C)alkyl, heteroaromatic, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, ~~or a group of formula R^3R^4N in which R^3 and R^4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group;~~ and

R^5, R^6, and R^7 represent hydrogen;

R^8 represents methyl;

~~R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of hydrogen, (1-6C)alkyl; aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or~~

~~two of R^5, R^6, R^7 and R^8 together with the carbon atom or carbon atoms to which they are attached form a (3-8C) carbocyclic ring; and the remainder of R^5, R^6, R^7 and R^8 represent hydrogen;~~ or a pharmaceutically acceptable salt thereof.

~~with the proviso that when R^2 represents R^3R^4N, then B is other than NR^aCONR^a or $CONR^a$.~~

19. (cancelled)

20. (currently amended) A method for improving memory or learning ability in a patient, which comprises administering to a patient in need thereof an effective amount of a compound of formula:



wherein

B is $CONR^a$, NR^aCO, NR^aCO_2 or NR^aCONR^a;

R^a represents hydrogen or (1-6C) alkyl,

q is ~~zero or~~ 1;

R^1 represents ~~an unsubstituted or substituted aromatic or heteroaromatic group~~ a phenyl substituted by thienyl;

R^2 represents hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, fluoro(1-6C)alkyl, chloro(1-6C)alkyl, (2-6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkylCO_2(1-4C)alkyl, phenyl(1-6C)alkyl, heteroaromatic, phenyl which is unsubstituted or substituted by halogen, (1-4C)alkyl or (1-4C)alkoxy, ~~or a group of formula R^3R^4N in which R^3 and R^4 each independently represents (1-4C)alkyl or, together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, morpholino, piperazinyl, hexahydroazepinyl or octahydroazocinyl group;~~ and

R^5, R^6, and R^7 represent hydrogen;

R^8 represents methyl;

~~R^5, R^6, R^7 and R^8 are each independently selected from the group consisting of hydrogen, (1-6C)alkyl; aryl(1-6C)alkyl; (2-6C)alkenyl; aryl(2-6C)alkenyl and aryl; or~~

~~two of R^5, R^6, R^7 and R^8 together with the carbon atom or carbon atoms to which they are attached form a (3-8C) carbocyclic ring; and the remainder of R^5, R^6, R^7 and R^8 represent hydrogen;~~ or a pharmaceutically acceptable salt thereof.

~~with the proviso that when R^2 represents R^3R^4N, then B is other than NR^aCONR^a or $CONR^a$.~~

21. (cancelled)